INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex, severe, chronic, and sometimes lifethreatening disease. Many factors contribute to the development of juvenile SLE (jSLE) including genetics, immune dysfunction and environmental factors 1 . jSLE is rare before 5
years-of-age, and where this occurs monogenic causes should be considered, particularly if there is a family history of SLE, and/or consanguinity. There is now an ever-expanding list of monogenic causes of SLE (Table 1) , and many present very early in life [2] [3] [4] [5] [6] . We describe two siblings who presented with early-onset jSLE in whom we identified a homozygous missense mutation in the Protein Kinase C Delta (PRKCD) gene. This report demonstrates the clinical importance of identifying monogenic causes of rare disease to provide a rapid and definitive diagnosis, help rationalize treatment, and to facilitate genetic counseling.
CASE
The index case presented at the age of 12-months with scarring alopecia, rash affecting the scalp, and a photosensitive malar rash (figure 1A). She also had hepatosplenomegaly and bruising of the skin ( Figure 1B ) and erythematous, non-pruritic, vasculitic rash affecting the hands and feet ( Figure 1C and D The pedigree of the family is shown in figure 2A . She was the second child of consanguineous parents (first cousins once removed, i.e. the father was the child of the mother's first cousin)
originally from Pakistan. The 5-year-old sister of the index case had identical symptoms and signs, which started at the age of 12-months. Her parents were initially healthy, although the mother subsequently developed SLE during her third pregnancy. This manifested as mild cutaneous malar rash, and arthralgia; but no evidence of pancytopenia or other organ involvement.
Both siblings were diagnosed with familial SLE, with fulfillment of 6 out of 11 of the American College of Rheumatology classification criteria: malar rash, photosensitivity, arthritis, haematological disorder, immunologic disorder and positive ANA 7 . Both patients were initially treated in the first instance with: pulse methylprednisolone (30 mg/kg for 3 days followed by oral prednisolone 2 mg/kg/day), hydroxychloroquine (5 mg/kg/day) and azathioprine (2 mg/kg/day). Despite this, over the next 6 months both children progressively deteriorated with pancytopenia with a platelet count in the range of 60,000 -84,000 cells/mL. Both siblings demonstrated only a transient response to further pulses of intravenous methylprednisolone and intravenous immunoglobulin (IVIG; 2g/kg, for persistent thrombocytopenia). Therefore, rituximab (750 mg/m 2 , repeated two weeks later) was given to the index case, which resulted in a rapid and sustained (13 months at the time of writing) clinical improvement, with complete normalisation of the full blood count, and normalisation of inflammatory markers. Rituximab (at the same dose) was then given to the older sibling, who unfortunately developed anaphylaxis during the second infusion, although still B-cell depleted successfully, and remains in clinical remission 12 months later.
Work up for suspected monogenic SLE
All experimental work was performed with ethical approval (ethics number: 08H071382) and with written informed consent from all participants. Both patients were screened using conventional Sanger sequencing for known monogenic causes of SLE for: TREX1, SAMHD1, C1qA, C1qB, and C1qC, all of which were negative (wild-type). Homozygosity mapping was therefore performed in both patients and both parents (see Supplementary Methods). Wholeexome sequencing (WES) was subsequently performed only in the index case (see Supplementary Methods). These studies revealed a homozygous missense mutation (c.1294G>T; p.Gly432Trp) in the PRKCD in the index case (see Supplementary Results for further details), subsequently confirmed using Sanger sequencing. The c.1294G>T substitution is a novel mutation not yet annotated in the dbSNP, the ClinSeq database 8 , 6500ESP 9 or the 1000 genomes project databases 10 . This homozygous c.1294G>T mutation was also confirmed in her affected sister using Sanger sequencing (figure 2B). Her currently asymptomatic 1-yearold brother was also homozygous for the same mutation. As expected, both parents were confirmed to be heterozygous carriers of the same mutation.
DISCUSSION
PRKCD is located on chromosome 3p21.31. It encodes protein kinase C delta (PKCδ), a member of serine/threonine kinase family that plays a role in apoptosis and proliferation of cells 11 . PKCδ is also known to play a role in B-cell negative selection 12 and has been shown to prevent proliferation of B and T cells in response to stimulation in the mouse model 13 . PKCδ deficient mice were found to have features of SLE including anti-double strand DNA autoantibodies, glomerulonephritis with IgG containing immune-complex.deposition and lymphocyte infiltration in multiple organs 13, 14 .
The p.Gly432Trp mutation affects the protein kinase activity domain which is located between amino acid 349 and 603
15
. Thus, this mutation is likely to cause a loss of function of the kinase activity of PKCδ. The p.Gly432Trp mutation is predicted to be deleterious in pathogenicity prediction algorithms (supplemental Table S Interestingly the mother, who is a heterozygous carrier of the mutation, developed SLE during pregnancy with her third child. The combined contribution of heterozygous carriage and hormonal changes occurring during pregnancy may be responsible for the new-onset of SLE during pregnancy 20 . The youngest brother aged eighteen months at the time of writing also has the homozygous mutation and is thus far asymptomatic but will be closely monitored for the development of symptoms.
CONCLUSIONS
We have described a rare monogenic form of jSLE caused by a novel but very likely damaging homozygous mutation affecting the active region of PRKCD. Identification of this additional disease causing variant of PRKCD provides further supportive evidence for this gene to be included in routine genetic screening for suspected monogenic SLE. Securing this molecular diagnosis not only provided us with a definitive diagnosis, but also explained the dramatic and complete therapeutic response to B-cell depletion (despite failing other therapies), and will direct the choices made for future treatment options. Since the list of monogenic causes of SLE is increasing (Table 1) , next-generation sequencing offers the opportunity to screen all the known genetic causes rapidly, and for a fraction of the cost of conventional sequencing, and
should be considered in all cases of early-onset (<5-years) jSLE, particularly for consanguineous families. 
